// App-Quantinova.ai

117P : Anti-HER2 therapy efficacy in HER2-negative metastatic breast cancer with HER2-amplified circulating tumor cells: results of the CirCe T-DM1 trial

Researchers

Presenter

  • F-C.Bidard

Principal Investigators

  • P.cottu

  • C.Dubot

  • L.Venat-Bouvet

  • A.Lortholary

  • H.Bourgeois

  • M.Bollet

  • V.Servent Hanon

  • E.Luporsi-Gely

  • M.Espie

  • S.Guiu

  • V.D'Hondt

  • V.Diras

  • M.P.Sablin

  • S.Neffati

  • F.Berger

  • J-Y.Pierga

  • W.Jacot

Medical Centers

  • Oncology Department, Institut Curie, Paris, France

  • Oncology, Hôpital René Huguenin - Institut Curie, St. Cloud, France

  • Rheumatology, University Hospital, Lille, France,

  • Medical Oncology, Centre Catherine de Sienne, Nantes, France

  • Medical Oncology, Clinique Victor Hugo Le Mans, Le Mans, France

  • Radiation Oncology, Clinique Hartmann, Levallois-Perret, France

  • Medical Oncology Dpt, Centre Oscar Lambret, Lille, France

  • Medical Oncology, Institut de Cancérologie de Lorraine - Alexis Vautrin, Vandoeuvre Les Nancy, France

  • Medical Oncology, Hôpital St. Louis, Paris, France

  • Department of Medical Oncology, Institut du Cancer de Montpellier, Montpellier, France

  • Medical Oncology, ICM Regional Cancer Institute of Montpellier, Montpellier, France

  • Department of Medical Oncology, Centre Eugène Marquis Rennes, France; Institut Curie, Paris, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • Circulating tumor cells

  • Human epidermal growth factor receptor 2

Drug/Treatment

  • Trastuzumab emtansine

Outcome

  • N/A

Study Design

  • N/A

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved